Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3972 results
MJFF, Prothena to accelerate new biomarkers discovery for Parkinson's disease
By PBR Staff Writer
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Irish biotechnology firm Prothena have entered into an agreement to jointly accelerate the discovery of new biomarkers and development of assays to measure Parkinson's disease (PD) progression.
Drug Research > Drug Discovery & Development > News
Myelin Repair Foundation and NIH begin clinical studies of guanabenz to treat multiple sclerosis
The Myelin Repair Foundation (MRF), in partnership with the National Institutes of Health (NIH), announced today that patients are now being enrolled in a clinical trial conducted to study guanabenz, an FDA-approved drug to treat high blood pressure that was identified by MRF-funded researchers as a potential therapeutic to reduce loss of myelin, in multiple sclerosis (MS) patients.
Drug Research > Drug Discovery & Development > News
TaiGen begins Phase I/II trial of burixafor in China to treat acute myeloid leukemia
By PBR Staff Writer
TaiGen Biotechnology Company has started a Phase I/II trial of burixafor in combination with two chemotherapeutic agents fludarabine and cytarabine in adults with relapsed or refractory acute myeloid leukemia (AML) in China.
Drug Research > Drug Discovery & Development > News
Tesaro completes target enrollment in Phase III Nova trial, begins Quadra trial of niraparib
Tesaro, an oncology-focused biopharmaceutical company, provided an update on its niraparib clinical development program.
Drug Research > Drug Discovery & Development > News
ContraFect begins Phase I trial of CF-301 for staph bloodstream infections
ContraFect, a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, has commenced screening of healthy volunteers in its Phase 1 clinical trial of CF-301.
Drug Research > Drug Discovery & Development > News
Eiger Bio reports interim results of lonafarnib-ritonavir combination in patients infected with hepatitis delta virus
Eiger BioPharmaceuticals has announced the presentation of interim results of Phase 2 data of lonafarnib in patients with chronic hepatitis delta viral (HDV) infection. Data were presented from the LOWR HDV program, enrolled at Ankara University Medical School, Turkey, in a country where HDV is endemic.
Drug Research > Drug Discovery & Development > News
aTyr's Resolaris gets FDA orphan drug designation for facioscapulohumeral muscular dystrophy
By PBR Staff Writer
Biotherapeutics company aTyr Pharma has received orphan drug designation from the US Food and Drug Administration (FDA) for its new drug Resolaris for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Drug Research > Drug Discovery & Development > News
Cardiff University scientists find potential root cause for asthma
By PBR Staff Writer
Scientists from the Cardiff University have discovered the potential root cause and a novel treatment for asthma, a chronic lung disease affecting 300 million people worldwide.
Drug Research > Drug Discovery & Development > News
ThromboGenics begins evaluation of Jetrea to treat retinal vein occlusion
By PBR Staff Writer
Belgium-based biopharmaceutical firm ThromboGenics has started evaluating Jetrea (ocriplasmin) as a potential treatment for retinal vein occlusion (RVO).
Drug Research > Drug Discovery & Development > News
Lilly reports positive results from Phase III trial of ixekizumab to treat psoriatic arthritis
By PBR Staff Writer
Eli Lilly and Company has announced that a Phase III trial (SPIRIT-P1) of its investigational medicine, ixekizumab, met the primary endpoint in the treatment of patients with psoriatic arthritis (PsA), a progressive, chronic and destructive disease.
Drug Research > Drug Discovery & Development > News
TetraLogic, Merck enter oncology clinical trial collaboration
By PBR Staff Writer
US-based biopharmaceutical firm TetraLogic Pharmaceuticals has entered into an oncology clinical study collaboration with Merck.
Drug Research > Drug Discovery & Development > News
Oncolytics' Reolysin gets orphan drug designation for malignant gliomas treatment
By PBR Staff Writer
Canadian biotechnology firm Oncolytics Biotech has secured orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its lead product candidate, Reolysin, to treat malignant glioma.
Drug Research > Drug Discovery & Development > News
Sun Pharma, Technion to develop new class of oncology drugs
By PBR Staff Writer
India-based Sun Pharmaceutical Industries and Israel's Technion University have entered into an exclusive worldwide research and license agreement for the development of new class of oncology drugs.
Drug Research > Drug Discovery & Development > News
Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH
By PBR Staff Writer
Reata Pharmaceuticals, a US-based developer of breakthrough medicines, has secured orphan drug designation from the FDA Office of Orphan Products Development (OOPD) for bardoxolone methyl to treat pulmonary arterial hypertension (PAH).
Drug Research > Drug Discovery & Development > News
US FDA modifies partial clinical hold on Tekmira's TKM-Ebola IND application
By PBR Staff Writer
The US Food and Drug Administration (FDA) has notified Tekmira Pharmaceuticals that the partial clinical hold on its investigational new drug (IND) application for TKM-Ebola, an anti-Ebola virus RNAi therapeutic, has been modified to permit repeat dosing of healthy volunteers at a dose of 0.24 mg/kg/day.
Drug Research > Drug Discovery & Development > News
61-75 of 3972 results